1

EPISODE · Apr 24, 2026 · 16 MIN

FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment

from 1nessAgency Insights

The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their

Episode metadata supplied by the publisher feed · Published Apr 24, 2026

Embed this episode

NOW PLAYING

FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment

0:00 16:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of 1nessAgency Insights?

This episode is 16 minutes long.

When was this 1nessAgency Insights episode published?

This episode was published on April 24, 2026.

Can I download this 1nessAgency Insights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!